ibn-iw-globe-2.png
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Eric Weisblum, CEO of Silo Pharma Inc.
May 18, 2022 08:17 ET | InvestorBrandNetwork (IBN)
LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment...
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease
May 09, 2022 07:00 ET | Athira Pharma, Inc.
– Study duration increased from 6 months to 18 months of open label treatment with fosgonimeton – BOTHELL, Wash., May 09, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late...
THE DAVOS ALZHEIMER’S COLLABORATIVE LAUNCHES INNOVATIVE EARLY DETECTION EFFORT
May 03, 2022 11:43 ET | Davos Alzheimer's Collaborative
New York, NY, May 03, 2022 (GLOBE NEWSWIRE) -- Unique global collaboration to prepare health systems for a future with new Alzheimer’s treatmentsPioneering use of blood-based biomarkers with...
silo.png
IBN (InvestorBrandNetwork) Coverage Initiated for Silo Pharma Inc.
March 30, 2022 08:30 ET | Silo Pharma Inc.
NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with...
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease at the 2022 AD/PD™ Congress
March 20, 2022 04:50 ET | Athira Pharma, Inc.
BOTHELL, Wash., March 20, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer’s Disease at AD/PD™ 2022 Congress
March 14, 2022 07:00 ET | Athira Pharma, Inc.
BOTHELL, Wash., March 14, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
ProMIS.jpg
ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM) and Related Neurological Disorders
March 10, 2022 07:00 ET | ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma to Present Preclinical Data at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
February 22, 2022 07:05 ET | Athira Pharma, Inc.
Oral presentation on neurotrophic and procognitive properties of the active metabolite of fosgonimeton in preclinical models First presentation of preclinical data from ATH-1020 candidate for...
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease
February 22, 2022 07:00 ET | Athira Pharma, Inc.
Fosgonimeton demonstrated a statistically significant improvement of Event-Related Potential (ERP) P300 latency as compared with placebo in Alzheimer’s disease patients Fosgonimeton was...
National Down Syndrome Organizations Launch Joint Effort To Change CMS Proposal Concerning Coverage For New Class Of Alzheimer’s Treatments
February 04, 2022 10:47 ET | National Down Syndrome Society
Atlanta, GA., Bismarck, ND., Burlington, MA., Denver, CO., Hoffman Estates, IL, NY, NY, Rockport, ME, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Down Syndrome Affiliates in Action (DSAIA), GiGi’s Playhouse...